The Federal Trade Commission said the three companies' practices have artificially inflated list prices for insulin.

The Federal Trade Commission has accused three major pharmacy benefit managers of inflating insulin prices, the agency said ...

The latest health news covers the European Medicines Agency's approval of Novo Nordisk's Wegovy for heart conditions linked ...

The federal government is suing some big pharmacy benefit managers over a system of drug rebates that regulators say has made the price of insulin soar for diabetic patients. Three companies that ...

Nike spent nearly $104 million on pay and benefits for John Donahoe during his near five-year tenure atop the sneaker-maker, ...

The Federal Trade Commission alleges that pharmacy benefits managers prioritized high rebates from drug makers for insulin over lower prices for consumers, leading to inflated out-of-pocket costs.